Highlights
• $12M equity funding facility secured
• Second European patent secured for CVac™ ovarian cancer treatment
• Commencement of patient treatment with CVac™ Cancer Therapy Vaccine
• Completion of first Share Purchase Plan
• Continuing towards US FDA approvals process for CVac™
• Progressing commercialisation of CVac™ in Australia
• Success of fellow cancer immune-therapy development company, Nasdaq-listed
Dendreon
______________________________________________________________________________
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $350.4M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.0¢ | $258.4K | 1.058M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 183431 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 89680 | 7 |
View Market Depth
| Last trade - 16.10pm 10/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |